EMA Backs New Delivery Route for Anti-CD38 Myeloma Drug

by | Mar 30, 2026 | Health

Spread the love
European regulators recommended a subcutaneous formulation for a key anti-CD38 therapy, offering clinicians and patients more flexible administration options for multiple myeloma.
Medscape News Europe

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments